GAO says FDA's foreign drug inspections can be improved

April 23, 2008

In testimony before a House subcommittee, the Government Accountability Office identifies weaknesses in the Food & Drug Administration's foreign drug inspection program.

Alarmed by the recent heparin contamination originating from China, the House Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, held a hearing yesterday on how the Food & Drug Administration can ensure drug safety. At the hearing, the Government Accountability Office